Zhifei Biologics' combined vaccine approved for clinical trials

Chongqing Zhifei Biological Products (SZSE:300122) announced that its subsidiary, Zhifei Green Bamboo Biopharmaceutical, has received approval from the National Medical Products Administration (NMPA) to commence clinical trials for its adsorbed acellular diphtheria, tetanus, and pertussis (component) and Haemophilus influenzae type b (combination) combined vaccine (DTaP-Hib). This quadrivalent vaccine aims to protect against pertussis, diphtheria, tetanus, and infections caused by Haemophilus influenzae type b, targeting a critical need for children under five. Zhifei highlights that the new vaccine features an upgraded pertussis antigen purification and preparation process, resulting in a higher quality, consistent product that could potentially replace DTaP vaccines in immunization programs. While the approval for clinical trials doesn't have a material impact on the company's short-term performance, successful development would broaden Zhifei's vaccine portfolio and strengthen its market position.